Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
   
Ask the Experts About

Understanding Your LabsUnderstanding Your Labs
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


Block gp120 on CD4 instead of attacking HIV?
Oct 11, 2003

Hi, I'm not an expert in virology, and I have a VERY limited understanding of the HIV infection mechanism; I was wondering however why we try and attack the HI Virus. Why not rather the CD4 receptors to the gp120 protein on the virus instead (if it is possible). If that could be done then the HI Virus would have no effect because it cannot fuse with cells to replicate. Maybe I'm sounding silly to the experts, but I'm curious to know if this is possible or not?

Response from Dr. Holodniy

There is already one fusion inhibitor (fuzeon) on the market, and others in clinical trials. Blocking the virus from attaching to cells is the subject of intense research and drug development.



Previous
VL drops then climbs, CD4 slow rise
Next
Viral Load Undetectable but CD4s Keep Dropping

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement